Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives $8.40 Average PT from Brokerages

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) have been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $8.40.

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Allogene Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Allogene Therapeutics in a research report on Friday, October 10th. UBS Group started coverage on shares of Allogene Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $8.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allogene Therapeutics in a research note on Wednesday, October 8th. Finally, Citigroup raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Friday, January 9th.

Insider Buying and Selling

In other news, CFO Geoffrey M. Parker sold 24,001 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $1.76, for a total transaction of $42,241.76. Following the completion of the sale, the chief financial officer directly owned 1,252,795 shares of the company’s stock, valued at $2,204,919.20. This represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Earl Martin Douglas sold 22,900 shares of Allogene Therapeutics stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.76, for a total value of $40,304.00. Following the completion of the transaction, the senior vice president directly owned 564,948 shares in the company, valued at $994,308.48. This represents a 3.90% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 215,855 shares of company stock valued at $378,426. 13.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. R Squared Ltd increased its position in shares of Allogene Therapeutics by 40.5% in the fourth quarter. R Squared Ltd now owns 86,215 shares of the company’s stock worth $118,000 after acquiring an additional 24,842 shares in the last quarter. Choreo LLC acquired a new position in Allogene Therapeutics in the 4th quarter worth approximately $51,000. Aberdeen Group plc grew its position in Allogene Therapeutics by 31.9% during the 4th quarter. Aberdeen Group plc now owns 2,086,332 shares of the company’s stock worth $2,858,000 after purchasing an additional 504,067 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Allogene Therapeutics by 5,267.6% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company’s stock valued at $30,000 after purchasing an additional 23,599 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its holdings in shares of Allogene Therapeutics by 27.3% in the third quarter. CANADA LIFE ASSURANCE Co now owns 39,730 shares of the company’s stock valued at $50,000 after purchasing an additional 8,519 shares in the last quarter. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Allogene Therapeutics

Here are the key news stories impacting Allogene Therapeutics this week:

• Neutral Sentiment: Short interest data appears anomalous (reported as 0 shares and NaN change); the report is not signaling meaningful short pressure or a clear change in bearish positioning. (Data likely unreliable; treat as neutral.)
• Negative Sentiment: Multiple senior executives sold shares on Feb. 2 — including CEO David D. Chang (95,269 shares at ~$1.80), EVP Zachary Roberts (35,700 at ~$1.77), CFO Geoffrey M. Parker (24,001 at ~$1.76), and other SVPs — reducing insider stakes by 1.8–5.8% for individual holders. These coordinated sales (total insider proceeds ~mid-six figures per filer) can be read as a negative near-term signal for sentiment and may pressure the stock despite today’s uptick. CEO Form 4 (SEC) EVP Form 4 (SEC) CFO Form 4 (SEC) SVP Form 4 (SEC) SVP Form 4 (SEC) SVP Form 4 (SEC)

Allogene Therapeutics Trading Up 3.4%

Allogene Therapeutics stock opened at $1.80 on Monday. Allogene Therapeutics has a 52 week low of $0.86 and a 52 week high of $3.78. The stock has a market cap of $404.51 million, a price-to-earnings ratio of -1.84 and a beta of 0.60. The company’s 50-day moving average price is $1.51 and its two-hundred day moving average price is $1.32.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. Research analysts expect that Allogene Therapeutics will post -1.28 earnings per share for the current fiscal year.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.